Peer-reviewed, large PSM study from Brazil finds: 
"regular use of ivermectin as a prophylactic agent was associated with significantly reduced COVID-19 infection, hospitalization, and mortality rates."

Ivermectin Prophylaxis Used for COVID-19: A Citywide, Prospective, Observational Study of 223,128 Subjects Using Propensity Score Matching

Statistical Analysis
The full underlying data for the present analysis were analyzed by two independent statisticians, and discrepancies were evaluated by a third statistics expert. In this outpatient study of those who tested positive for SARS-CoV-2, the mortality rate was evaluated according to each parameter that was adjusted against other variables (for multivariate regression analysis) and used for balancing and matching groups, including age intervals, sex, history of smoking, prophylactic ivermectin use, T2D, asthma, COPD, cardiovascular diseases and other pulmonary diseases, hypertension, current cancer (any type), and history of stroke and/or MI.

Before matching, a generalized linear mixed model was employed, assuming the binomial distribution for the residues and including the fixed classificatory effects of each of these parameters. Age intervals were adjusted for the evaluation of ivermectin prophylactic use as an independent predictor of death from COVID-19. Unadjusted and multivariate Poisson-adjusted probabilities to survive from COVID-19 (p-value), according to each parameter, were provided.

PSM was performed for mortality risk between ivermectin and non-ivermectin users. COVID-19 infection rate and risk of dying were also calculated for variables. After PSM, a second adjustment ("double adjustment") with multivariate linear regression was performed for residual variables [33,34].

There were no missing data since the registry system design mandated that all data variables be filled to be formally included in the registry. Only erroneously entered (illogical) data were found. In such instances, a medical record review was performed to obtain accurate data. The program used for the analysis was the Statistical Analysis Software (SAS/STAT) (SAS Institute Inc., Cary, NC). For transparency reasons, two datasets of the 7,345 COVID-19 cases and the 113,845 participating subjects considered for the present analysis will be made public upon peer-reviewed publication.

A detailed description of the data considered for the present analysis is illustrated in Figure 1. Of the 220,517 citizens of Itajaí without COVID-19 until July 7, 2020, 159,561 were above 18 years old. Of the 159,561 citizens above 18 years old without COVID-19 until July 7, 2020, 113,845 (71.3% of the population above 18 years old) received ivermectin before being infected by COVID-19. A total of 45,716 citizens (28.7%) did not receive or did not want to receive ivermectin during the program, including as a prophylactic or as a treatment after having COVID-19.

For anyone looking for Ivermectin and/or HCQ this is very helpful information. will prescribe both Ivermectin and HCQ they see so many patients a day via telehealth (using a messaging service) starting at 9am. They are free but accept donations. is based out of Florida and will prescribe and ship ivermectin to all over the US. for non-emergent ivermectin and even budesonide. They are the cheapest and have multiple strength options. 
Push Health has also been recommended by many and offer ivermectin via telehealth.

Source - Cureus   
Authors -  Lucy Kerr, Flavio A. Cadegiani, Fernando Baldi, Raysildo B. Lobo, Washington Luiz O. Assagra, Fernando Carlos Proença, Pierre Kory, Jennifer A. Hibberd, Juan J. Chamie-Quintero

Tags: #ivermectin #telehealth #HCQ #Myfreedoctor #prescribe #IVM #prescription #covid19 #wherecanigetivermectin #howdoigetivm #wheredoigethcq #howdoigethcq #novax #donotcomply #donotconsent

Add Comment